JUN and cancer: In addition, overexpressed JUN partially rescued the migration of breast cancer cells treated with Ponatinib (P < 0.001), which indicated that c-Jun might be a major mediator of Ponatinib’s inhibitory effect on cancer cell migration (Figs. 5M, 5N, S6C and S8A).